Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluzoparil + temozolomide in primary glioblastoma (Phase II)
ChiCTR2200060227Phase 2Not yet recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- May 2022
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fluzoparib and temozolomide in glioblastoma (GBM), sponsored by Shandong Cancer Hospital. Primary endpoints: Progression-free survival (PFS) and Objective response rate (ORR). Planned start May 2022; status: not yet recruiting.
02
Drugs
fluzoparibtemozolomide
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on ChiCTR2200060227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200060227.